Message Font: Serif | Sans-Serif
No. of Recommendations: 2

MARTINSRIED, Germany and MUNICH, Germany, April 3 /PRNewswire/ -- MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today the achievement of an important milestone in its collaboration with ImmunoGen, Inc. (Nasdaq: IMGN - news). MorphoSys successfully generated antibodies meeting all success criteria against a cancer target provided by ImmunoGen. This achievement triggered a milestone payment from ImmunoGen to MorphoSys.

``Our success today is yet another demonstration of our ability to use HuCAL® to generate precisely engineered human antibodies against a variety of targets,' said Dr. Thomas von Ruden, Chief Scientific Officer, MorphoSys AG.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.